Q-omics provides the consensus-scored LINC00484 profile across patient tissues and cancer cell-line models. LINC00484 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC00484 is differentially expressed in 13, with the highest sampling consensus in LUSC. Additionally, LINC00484 RNA expression shows 14,397 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight SKCM, LUSC, and ESCA as cancer lineages where LINC00484 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00484 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00484 survival associations across molecular data types. LINC00484 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00484 RNA expression–survival associations across cancer types. High LINC00484 expression shows unfavorable associations in LGG, but favorable associations in SKCM, HNSC, THCA, CHOL and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC00484 RNA expression.
This table summarizes LINC00484 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00484. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00484 shows lower tumor expression in LUSC, COAD, THCA, BRCA, BLCA and KIRC. The LUSC box plot shows higher LINC00484 RNA expression in normal versus tumor tissue (log2 FC = −0.113, t-test p < 0.001).
This table shows molecular features associated with LINC00484 in patient tissues and cancer cell lines. In patient samples, LINC00484 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
